Skip to main content
Premium Trial:

Request an Annual Quote

QuantuMDx, Scienion Partner to Commercialize Nanowire Biosensor

NEW YORK (GenomeWeb) – QuantuMDx and German microarray firm Scienion today announced that they have partnered to commercialize QuantuMDx's multiplexed nanowire array technology.

The nanowire technology is a component of QuantuMDx's Q-Poc handheld molecular diagnostic device. Molecular probes are printed on each nanowire in the array, raising multiplex potential.

The firms said in a statement that QuantuMDx has purchased Scienion's sciFlexarrayer SX, and that they will use this ultra-low-volume liquid handling technology to transfer biological material onto QuantuMDx's biosensor.

The firms also said they will launch several development projects as they push to begin mass manufacturing the nanowire biosensor.

In March Scienion's microarray manufacturing process received ISO 13485 certification

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.